Quidel enlisted ICS' multidisciplinary team to be the application developer of the next-generation, fully integrated molecular diagnostic system for its Savanna platform.
The low-cost, point-of-care testing platform allows for easy rapid results for disease states and conditions such as COVID-19, MRSA and HIV.
The Savanna project started with UX design leading to an intuitive CLIA-waived touchscreen interface and an extensible processing architecture. It also includes software applications and powerful, forward-looking cybersecurity for its fleet in the field.
With Savanna, Quidel will deploy a future-proof in-vitro diagnostics platform that's flexible, scalable, configurable and secure.
In its collaboration with ICS, Quidel convenes best-practices from usability, cybersecurity, cloud and user management on an embedded touch-screen platform.
ICS has collaborated with Quidel on other point-of-care technologies, which have received Emergency Use Authorization from the US Food and Drug Administration.
ICS assisted Quidel in bringing development in-house, setting up a new continuous integration system to build the software and run automated unit tests, enabling the generation of new software releases following a development and test process that meets the stringent requirements of medical devices.
ICS also designed and implemented new product features, including an IoT-based facility for software updates and remote device management.
At the intersection of custom software development, engineering and UX design, Integrated Computer Solutions (ICS) has been helping Fortune 1000 companies create transformative products for over 30 years.
ICS is headquartered in Waltham, Mass., with offices in Sunnyvale, California and Ottawa, Ontario.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval